86
Views
4
CrossRef citations to date
0
Altmetric
Review Article

Is There NO Treatment For Severe Sepsis?

&
Pages 34-38 | Published online: 13 Dec 2016

References

  • Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl 3 Med. 2003; 348:138–50.
  • Bernard GR, Vincent SI, Laterre PF, et al. Efficacy and safety of recombinant human activated protein c for severe sepsis. N Engl 3 Med. 2001; 344:699–709.
  • Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock:The cub-rea network. Am 3 Respir Crit Care Med. 2003; 168:165–72.
  • Annane D, Bellissant E, Cavaillon 3M. Septic shock. Lancet. 2005; 365:63–78.
  • Annane D, Bellissant E, Bollaert PE, Briegel S, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock:A systematic review and meta-analysis. BMJ. 2004; 329:480–9.
  • Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the united states from 1979 through 2000. N Engl 3 Med. 2003; 348:1546–54.
  • Hsia DC, Krushat WM, Fagan AB, Tebbutt JA, Kusserow RP. Accuracy of diagnostic coding for medicare patients under the prospective-payment system. N Engl 3 Med. 1988; 318:352–5.
  • Iezzoni LI. Assessing quality using administrative data Ann Intern Med. 1997; 127:666–74.
  • Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med. 2003; 9:517–24.
  • Nguyen HB, Rivers EP, Abrahamian FM, et al. Severe sepsis and septic shock:Review of the literature and emergency department management guidelines. Ann Emerg Med. 2006; 48:28–54.
  • Russell JA. Management of sepsis. N Engl 3 Med. 2006; 355:1699–713.
  • Ziegler EJ, Fisher O, Jr., Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with ha-la human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The ha-la sepsis study group. N Engl 3 Med. 1991; 324:429–36.
  • Bennet IL, Finland M. The effectiveness of hydrocortisone in the management of severe infections:Cooperative study group. JAMA. 1963; 183:462–5.
  • Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock:A meta-analysis. Crit Care Med. 1995; 23:1294–303.
  • Abraham E, Laterre PF, Garbino S, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock:A randomized, double-blind, placebo-controlled, multicenter phase iii trial with 1, 342 patients. Crit Care Med. 2001; 29:503–10.
  • Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. Tnf-alpha mab sepsis study group. JAMA. 1995; 273:934–41.
  • Fisher O., Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase iii rhillra sepsis syndrome study group. Jama. 1994; 271:1836–43.
  • Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis. 2002; 34:1084–93.
  • Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis:A randomized controlled trial. JAMA. 2003; 290:238–47.
  • Carraway MS, Welty-Wolf KE, Miller DL, et al. Blockade of tissue factor:Treatment for organ injury in established sepsis. Am 3 Respir Crit Care Med. 2003; 167:1200–9.
  • Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin iii in severe sepsis:A randomized controlled trial. JAMA. 2001; 286:1869-78.
  • Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Meta-analysis:The effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med. 2004; 141:47–56.
  • Keh D, Sprung CL. Use of corticosteroid therapy in patients with sepsis and septic shock:An evidence-based review. Crit Care Med. 2004; 32:S527–33.
  • Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC. Novel therapies for sepsis:A review. 3 Trauma. 2005; 58:867–74.
  • Sprung CL, Annane D, Briegel S, et al. Corticosteroid therapy of septic shock (corticus). Am 3 Respir Crit Care Med. 2007; 175:A507.
  • Choi G, Schultz MJ, Levi M, van der Poll T. The relationship between inflammation and the coagulation system. Swiss Med Wkly. 2006; 136:139–44.
  • Esmon CT. The protein c anticoagulant pathway. Arterioscler Thromb. 1992; 12:135–45.
  • Gresele P, Momi S, Berrettini M, et al. Activated human proteinc prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest. 1998; 101:667–76.
  • Dettenmeier P, Swindell B, Stroud M, Arkins N, Howard A. Role of activated protein c in the pathophysiology of severe sepsis. Am J Crit Care. 2003; 12:518–24.
  • De Pont AC, Bakhtiari K, Hutten BA, et al. Recombinant human activated protein c resets thrombin generation in patients with severe sepsis - a case control study. Crit Care. 2005; 9:R490–7.
  • Friedrich JO, Adhikari NK, Meade MO. Drotrecogin alfa (activated):Does current evidence support treatment for any patients with severe sepsis? Crit Care. 2006; 10:145.
  • Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein c treatment for severe sepsis. N Engl 3 Med. 2002; 347:1027–30.
  • Eichacker PQ, Natanson C. Increasing evidence that the risks of rhapc may outweigh its benefits. Intensive Care Med. 2007; 33:396–9.
  • Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl 3 Med. 2005; 353:1332–41.
  • Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis:A multicentre phase iii randomised controlled trial. Lancet. 2007; 369:836–43.
  • Marti-Carvajal A, Salanti G, Cardona A. Human recombinant activated protein c for severe sepsis. Cochrane Database Syst Rev. 2007:CD004388.
  • Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. 3 Exp Med. 2007; 204:2439–48.
  • Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288:373–6.
  • Ignarro U, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987; 84:9265–9.
  • almer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987; 327:524–6.
  • Lowenstein O, Michel T. What’s in a name? Enos and anaphylactic shock. 3 Clin Invest. 2006; 116:2075–8.
  • Kilbourn RG, Fonseca GA, Griffith OW, et al. Ng-methyl-l-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med. 1995; 23:1018-24.
  • Kilbourn RG, Gross SS, Jubran A, et al. Ng-methyl-l-arginine inhibits tumor necrosis factor-induced hypotension:Implications for the involvement of nitric oxide. Proc Natl Acad Sci U S A. 1990; 87:3629–32.
  • Kilbourn RG, Jubran A, Gross SS, et al. Reversal of endotoxin-mediated shock by ng-methyl-l-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun. 1990; 172:1132–8.
  • Kilbourn RG, Gross SS, Lodato RF, et al. Inhibition ofinterleukin-l-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-l-alpha-induced hypotension by n omega-amino-l-arginine. 3 Natl Cancer Inst. 1992; 84:1008–16.
  • Thiemermann C, Szabo C, Mitchell JA, Vane JR. Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci USA. 1993; 90:267–71.
  • Thiemermann C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur 3 Pharmacol. 1990; 182:591–5.
  • Avontuur JA, Tutein Nolthenius RP, van Bodegom JW, Bruining HA. Prolonged inhibition of nitric oxide synthesis in severe septic shock:A clinical study. Crit Care Med. 1998; 26:660–7.
  • Lopez A, Lorente JA, Steingrub S, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546c88:Effect on survival in patients with septic shock. Crit Care Med. 2004; 32:21–30.
  • Petros A, Bennett D, Valiance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991; 338:1557–8.
  • Petros A, Lamb G, Leone A, Moncada S, Bennett D, Valiance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res. 1994; 28:34–9.
  • Cobb JP, Natanson C, Hoffman WD, et al. N omega-amino-I-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. 3 Exp Med. 1992; 176:1175–82.
  • Klabunde RE, Ritger RC. Ng-monomethyl-l-arginine (nma) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxic shock. Biochem Biophys Res Commun. 1991; 178:1135–40.
  • Liaudet L, Rosselet A, Schaller MD, Markert M, Perret C, Feihl F. Nonselective versus selective inhibition of inducible nitric oxide synthase in experimental endotoxic shock. 3 Infect Dis. 1998; 177:127–32.
  • Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest. 1992; 90:1718–25.
  • Teale DM, Atkinson AM. L-canavanine restores blood pressure in a rat model of endotoxic shock. Eur 3 Pharmacol. 1994; 271:87–92.
  • Ichinose F, Buys ES, Neilan TG, et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 prevents myocardial dysfunction in murine models of septic shock. Circ Res. 2007; 100:130–9.
  • Yamashita T, Kawashima S, Ohashi Y, et al. Resistance to endotoxin shock in transgenic mice overexpressing endothelial nitric oxide synthase. Circulation. 2000; 101:931–7.
  • Feihl F, Waeber B, Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? Pharmacol Ther. 2001; 91:179–213.
  • Cauwels A, Bultinck S, Brouckaert P. Dual role of endogenous nitric oxide in tumor necrosis factor shock:Induced NO tempers oxidative stress. Cell Mol Life Sci. 2005; 62:1632–40.
  • Cauwels A, Van Molle W, Janssen B, et al. Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. Immunity. 2000; 13:223–31.
  • Cobb JP, Hotchkiss RS, Swanson PE, et al. Inducible nitric oxide synthase (iNOS) gene deficiency increases the mortality of sepsis in mice. Surgery. 1999; 126:438–42.
  • Laubach VE, Foley PL, Shockey KS, Tribble CG, Kron IL. Protective roles of nitric oxide and testosterone in endotoxemia:Evidence from NOS-2-deficient mice. Am 3 Physiol. 1998; 275:H2211–8.
  • Nicholson SC, Grobmyer SR, Shiloh MU, et al. Lethality of endotoxin in mice genetically deficient in the respiratory burst oxidase, inducible nitric oxide synthase, or both. Shock. 1999; 11:253–8.
  • Cauwels A. Nitric oxide in shock. Kidney Int. 2007; 72:557–95.
  • Li CQ, Wogan GN. Nitric oxide as a modulator of apoptosis. Cancer Lett. 2005; 226:1–15.
  • Afulukwe IF, Cohen RI, Zeballos GA, Iqbal M, Scharf SM. Selective NOS inhibition restores myocardial contractility in endotoxemic rats; however, myocardial NO content does not correlate with myocardial dysfunction. Am I Respir Crit Care Med. 2000; 162:21–6.
  • Nilsson BO. Biological effects of aminoguanidine:An update. Inflamm Res. 1999; 48:509–15.
  • Bone HG, Fischer SR, Schenarts ISS, McGuire R, Traber LD, Traber DL. Continuous infusion of pyridoxalated hemoglobin polyoxyethylene conjugate in hyperdynamic septic sheep. Shock. 1998; 10:69–76.
  • Miura K, Yamanaka S, Ebara T, et al. Effects of nitric oxide scavenger, carboxy-PTIO on endotoxin-induced alterations in systemic hemodynamics in rats. Jpn 3 Pharmacol. 2000; 82:261–4.
  • Dickinson E, Tuncer R, Nadler E, et al. NOX, a novel nitric oxide scavenger, reduces bacterial translocation in rats after endotoxin challenge. Am J Physiol. 1999; 277:G1281–7.
  • Yoshida M, Akaike T, Wada Y, et al. Therapeutic effects of imidazolineoxyl n-oxide against endotoxin shock through its direct nitric oxide-scavenging activity. Biochem Biophys Res Commun. 1994; 202:923–30.
  • Kinasewitz G, Malcynski S, Steingrub Jea, Balk R, De Angelo I. Pyridoxalated hemoglobin polyoxyethylene (PHP) in distributive shock. Crit Care Med. 2004; 32 (Suppl 12):A11.
  • Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic gmp. Pharmacol Rev. 2000; 52:375–414.
  • Cauwels A, Brouckaert P. Critical role for small and large conductance calcium-dependent potassium channels in endotoxemia and TNF toxicity. Shock. 2007; Publish Ahead of Print Sept, 13.
  • Donati A, Preiser JC. Methylene blue: An old-timer or a compound ready for revival? Crit Care Med. 2006; 34:2862-3.
  • Donati A, Conti G, Loggi S, et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med. 2002; 30:2271–7.
  • Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock:A pilot, randomized, controlled study. Crit Care Med. 2001; 29:1860–7.
  • Preiser JC, Lejeune P, Roman A, et al. Methylene blue administration in septic shock:A clinical trial. Crit Care Med. 1995; 23:259–64.
  • Ahern GP, Klyachko VA, Jackson MB. cGMP and S-nitrosylation:Two routes for modulation of neuronal excitability by NO. Trends Neurosci. 2002; 25:510–7.
  • Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994; 368:850–3.
  • Tanaka Y, Koike K, Toro L. Maxik channel roles in blood vessel relaxations induced by endothelium-derived relaxing factors and their molecular mechanisms. 3 Smooth Muscle Res. 2004; 40:125–53.
  • Waldron GJ, Cole WC. Activation of vascular smooth muscle K+ channels by endothelium-derived relaxing factors. Clin Exp Pharmacol Physiol. 1999; 26:180–4.
  • Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001; 345:588–95.
  • Buckley JF, Singer M, Clapp LH. Role of KATP channels in sepsis. Cardiovasc Res. 2006; 72:220–30.
  • Bhatia M. Hydrogen sulfide as a vasodilator. IUBMB Life. 2005; 57:603–6.
  • Landry DW, Oliver JA. The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. 3 Clin Invest. 1992; 89:2071–4.
  • Sorrentino R, d’Emmanuele di Villa Bianca R, Lippolis L, Sorrentino L, Autore G, Pinto A. Involvement of ATP-sensitive potassium channels in a model of a delayed vascular hyporeactivity induced by lipopolysaccharide in rats. Br 3 Pharmacol. 1999; 127:1447–53.
  • VaneIli G, Hussain SN, Aguggini G. Glibenclamide, a blocker of ATP-sensitive potassium channels, reverses endotoxin-induced hypotension in pig. Exp Physiol. 1995; 80:167–70.
  • Wu CC, Thiemermann C, Vane JR. Glibenclamide-induced inhibition of the expression of inducible nitric oxide synthase in cultured macrophages and in the anaesthetized rat. Br 3 Pharmacol. 1995; 114:1273–81.
  • da Silva-Santos JE, Terluk MR, Assreuy J. Differential involvement of guanylate cyclase and potassium channels in nitric oxide-induced hyporesponsiveness to phenylephrine in endotoxemic rats. Shock. 2002; 17:70–6.
  • Warrillow S, Egi M, Bellomo R. Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med. 2006; 34:980–5.
  • Oliver JA, Landry DW. Potassium channels and septic shock. Crit Care Med. 2006; 34:1255–7.
  • Robertson BE, Schubert R, Hescheler S, Nelson MT. cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells. Am 3 Physiol. 1993; 265:C299–303.
  • Wanstall JC, Homer KL, Doggrell SA. Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. Curr Vasc Pharmacol. 2005; 3:41–53.
  • Archer SL, Gragasin FS, Wu X, et al. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11, 12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK (Ca) channels. Circulation. 2003; 107:769–76.
  • Ellis A, Triggle CR. Endothelium-derived reactive oxygen species:Theirrelationshiptoendothelium-dependenthyperpolarization and vascular tone. Can J Physiol Pharmacol. 2003; 81:1013–28.
  • Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor:Where are we now? Arterioscler Thromb Vasc Biol. 2006; 26:1215-25.
  • Clayton NP, LeDuc BW, Kelly la Effect of potassium channel and cytochrome p450 inhibition on transient hypotension and survival during lipopolysaccharide-induced endotoxic shock in the rat. Pharmacology. 2005; 73:113–20.
  • Pickkers P, Dorresteijn MJ, Bouw MP, van der Hoeven JG, Smits P. In vivo evidence for nitric oxide-mediated calcium-activated potassium-channel activation during human endotoxemia. Circulation. 2006; 114:414–21